Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
66.70
+0.11 (+0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
47
48
Next >
On Earth Day, Gilead Marks Strides in Environmental Sustainability
April 29, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Emissions
Gilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus
April 28, 2022
Gilead Sciences, Inc. (NASDAQ: GILD) reported firs
Via
Benzinga
Gilead Sciences Crushes First-Quarter Views As Covid Drug Adds $1.5 Billion
April 28, 2022
The company said quarterly sales rose 2% excluding the impact of Veklury.
Via
Investor's Business Daily
Recap: Gilead Sciences Q1 Earnings
April 28, 2022
Gilead Sciences (NASDAQ:GILD) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Gilead Sciences Announces First Quarter 2022 Financial Results
April 28, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead's Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients
April 26, 2022
Via
Benzinga
FDA Lifts Partial Clinical Hold On Gilead's MDS, AML Magrolimab Studies
April 12, 2022
The FDA has
Via
Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
April 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Gilead Sciences's Earnings Outlook
April 27, 2022
Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Gilead...
Via
Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
April 26, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
The Daily Biotech Pulse - Tuesday, April,26
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
7 Dividend Stocks Paying Over 5% to Buy Now
April 26, 2022
Stock markets will return less this year as interest rates rise and cause a recession, so investors should demand higher yield.
Via
InvestorPlace
Gilead Sciences Announces Support for the Robert A. Winn Diversity in Clinical Trials Award Program
April 26, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19
April 25, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Several New Studies Presented at ECCMIC 2022 Confirm Veklury® (Remdesivir) Activity in Treating COVID-19
April 24, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial
April 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
WHO Backs Pfizer's Oral COVID Antiviral Therapy For High-Risk Patients
April 22, 2022
Via
Benzinga
Pfizer: What Comes After the Covid-19 Fire?
April 21, 2022
Success with Pfizer's Covid-19 vaccine maintains the PFE stock status as a dividend aristocrat, but don't expect miracles.
Via
InvestorPlace
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
April 21, 2022
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.
Via
Benzinga
NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 Therapy
April 21, 2022
Via
Benzinga
If You Invested $1000 In Gilead Sciences 20 Years Ago, Here's How Much You Would Have Today
April 20, 2022
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.99% on an annualized basis producing an average annual return of 15.38%. Currently, Gilead Sciences has a market...
Via
Benzinga
Mom Celebrates Sons' Milestones: Julie's CAR T-cell Therapy Journey
April 20, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
April 19, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
The Translatinx Network Helps a Resilient Community 'Live Its Truth'
April 18, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Tour for Diversity in Medicine, Gilead Sciences and the Advisory Group to SHC Vaccine Equity Program to Receive Booker T. Washington Award From National Minority Quality Forum
April 15, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences to Release First Quarter 2022 Financial Results on Thursday, April 28, 2022
April 14, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Why Is Sierra Oncology (SRRA) Stock Up Today?
April 13, 2022
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring.
Via
InvestorPlace
Four Questions With Anu Osinusi: Gilead's Commitment to People Living With Viral Hepatitis
April 13, 2022
SOURCE: Gilead Sciences
Via
3BL Media
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
April 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.